EyePoint Pharmaceuticals
EYPT
About: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Employees: 144
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
62% more capital invested
Capital invested by funds: $401M [Q1] → $649M (+$247M) [Q2]
42% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 36
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
7% less funds holding
Funds holding: 151 [Q1] → 141 (-10) [Q2]
7.62% less ownership
Funds ownership: 107.77% [Q1] → 100.15% (-7.62%) [Q2]
30% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 30
75% less call options, than puts
Call options by funds: $2.85M | Put options by funds: $11.4M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Chardan Capital
Daniil Gataulin
|
$27
|
Buy
Maintained
|
7 Aug 2025 |
|
HC Wainwright & Co.
Yi Chen
|
$23
|
Buy
Maintained
|
6 Aug 2025 |
|
RBC Capital
Lisa Walter
|
$28
|
Outperform
Initiated
|
17 Jun 2025 |
Financial journalist opinion
Based on 3 articles about EYPT published over the past 30 days
